Cargando…

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and...

Descripción completa

Detalles Bibliográficos
Autores principales: Staehli Hodel, Eva Maria, Guidi, Monia, Zanolari, Boris, Mercier, Thomas, Duong, Socheat, Kabanywanyi, Abdunoor M, Ariey, Frédéric, Buclin, Thierry, Beck, Hans-Peter, Decosterd, Laurent A, Olliaro, Piero, Genton, Blaise, Csajka, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720542/
https://www.ncbi.nlm.nih.gov/pubmed/23841950
http://dx.doi.org/10.1186/1475-2875-12-235
_version_ 1782277957911314432
author Staehli Hodel, Eva Maria
Guidi, Monia
Zanolari, Boris
Mercier, Thomas
Duong, Socheat
Kabanywanyi, Abdunoor M
Ariey, Frédéric
Buclin, Thierry
Beck, Hans-Peter
Decosterd, Laurent A
Olliaro, Piero
Genton, Blaise
Csajka, Chantal
author_facet Staehli Hodel, Eva Maria
Guidi, Monia
Zanolari, Boris
Mercier, Thomas
Duong, Socheat
Kabanywanyi, Abdunoor M
Ariey, Frédéric
Buclin, Thierry
Beck, Hans-Peter
Decosterd, Laurent A
Olliaro, Piero
Genton, Blaise
Csajka, Chantal
author_sort Staehli Hodel, Eva Maria
collection PubMed
description BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. METHODS: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM(®)). RESULTS: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs’ pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. CONCLUSION: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites.
format Online
Article
Text
id pubmed-3720542
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37205422013-07-26 Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients Staehli Hodel, Eva Maria Guidi, Monia Zanolari, Boris Mercier, Thomas Duong, Socheat Kabanywanyi, Abdunoor M Ariey, Frédéric Buclin, Thierry Beck, Hans-Peter Decosterd, Laurent A Olliaro, Piero Genton, Blaise Csajka, Chantal Malar J Research BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. METHODS: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM(®)). RESULTS: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs’ pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. CONCLUSION: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites. BioMed Central 2013-07-10 /pmc/articles/PMC3720542/ /pubmed/23841950 http://dx.doi.org/10.1186/1475-2875-12-235 Text en Copyright © 2013 Staehli Hodel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Staehli Hodel, Eva Maria
Guidi, Monia
Zanolari, Boris
Mercier, Thomas
Duong, Socheat
Kabanywanyi, Abdunoor M
Ariey, Frédéric
Buclin, Thierry
Beck, Hans-Peter
Decosterd, Laurent A
Olliaro, Piero
Genton, Blaise
Csajka, Chantal
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title_full Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title_fullStr Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title_full_unstemmed Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title_short Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
title_sort population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in cambodian and tanzanian malaria patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720542/
https://www.ncbi.nlm.nih.gov/pubmed/23841950
http://dx.doi.org/10.1186/1475-2875-12-235
work_keys_str_mv AT staehlihodelevamaria populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT guidimonia populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT zanolariboris populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT mercierthomas populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT duongsocheat populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT kabanywanyiabdunoorm populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT arieyfrederic populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT buclinthierry populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT beckhanspeter populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT decosterdlaurenta populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT olliaropiero populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT gentonblaise populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients
AT csajkachantal populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients